Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23618912 | 0.84 | ACHE (0.55) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL30702212 | 0.83 | MAPT (0.56) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL3948845 | 0.83 | MAPT (0.56) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL29458360 | 0.82 | ACHE (0.53) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL599710 | 0.82 | ACHE (0.53) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL5311960 | 0.81 | KMT2A (0.55) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL1000380 | 0.81 | ACHE (0.51) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL19836626 | 0.81 | ALDH1A1 (0.54) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL6116289 | 0.81 | METAP1 (0.55) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL29476747 | 0.81 | ACHE (0.51) | ACHEKDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925330-A | Preparation method of altimezole | 上海阿达玛斯试剂有限公司 | 2020-11-13 | — | — | CN | claimed |
| US-11795132-B2 | Application of metal hydride/palladium compound system in preparation of 1,3-dicarbonyl compound in cascade reaction of electron-deficient alkene compound | SOOCHOW UNIVERSITY (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11795132-B2 | Application of metal hydride/palladium compound system in preparation of 1,3-dicarbonyl compound in cascade reaction of electron-deficient alkene compound | SOOCHOW UNIVERSITY (CN) | 2023-10-24 | — | — | US | disclosed |
| CN-112458001-B | Bacterial strain capable of degrading polycyclic aromatic hydrocarbon and application thereof | 上海交通大学 | 2022-09-27 | — | — | CN | disclosed |
| US-11180437-B2 | Method for preparing 1,3-dicarbonyl compound based on metal hydride/palladium compound system | SOOCHOW UNIVERSITY (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20210206707-A1 | APPLICATION OF METAL HYDRIDE/PALLADIUM COMPOUND SYSTEM IN PREPARATION OF 1,3-DICARBONYL COMPOUND IN CASCADE REACTION OF ELECTRON-DEFICIENT ALKENE COMPOUND | SOOCHOW UNIVERSITY (CN) | 2021-07-08 | — | — | US | disclosed |
| US-20210206708-A1 | METHOD FOR PREPARING 1,3-DICARBONYL COMPOUND BASED ON METAL HYDRIDE/PALLADIUM COMPOUND SYSTEM | SOOCHOW UNIVERSITY (CN) | 2021-07-08 | — | — | US | disclosed |
| CN-112225700-A | Preparation method of altimezole | 湖南新合新生物医药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-111925330-A | Preparation method of altimezole | 上海阿达玛斯试剂有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111925330-A | Preparation method of altimezole | 上海阿达玛斯试剂有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-1280779-B1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORP (FI) | 2005-08-24 | — | — | EP | disclosed |
| EP-1280779-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2003-02-05 | — | — | EP | disclosed |
| US-6362211-B2 | FOR THERAPY OF NEUROLOGICAL, PSYCHIATRIC OR COGNITION DISORDER, DIABETES, LIPOLYTIC DISORDER, ORTHOSTATIC HYPOTENSION, OR SEXUAL DYSFUNCTION | ORION CORPORATION (FI) | 2002-03-26 | — | — | US | disclosed |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ORION CORPORATION (FI) | 2002-01-31 | — | — | US | disclosed |
| WO-2001085698-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2001-11-15 | — | — | WO | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206708-A1 | METHOD FOR PREPARING 1,3-DICARBONYL COMPOUND BASED ON METAL HYDRIDE/PALLADIUM COMPOUND SYSTEM | ODC1, HVCN1, PDCD1 | ACHE 3532/4885KDM4E 1311/4885MEN1 1294/4885 |
| US-11180437-B2 | Method for preparing 1,3-dicarbonyl compound based on metal hydride/palladium compound system | ODC1, HVCN1, PDCD1 | ACHE 3532/4885KDM4E 1311/4885MEN1 1294/4885 |
| US-20210206707-A1 | APPLICATION OF METAL HYDRIDE/PALLADIUM COMPOUND SYSTEM IN PREPARATION OF 1,3-DICARBONYL COMPOUND IN CASCADE REACTION OF ELECTRON-DEFICIENT ALKENE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HVCN1, HRH4 | ACHE 3399/4885KDM4E 924/4885MEN1 1285/4885 |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ADRB2, ADRB1, ADRA1A | ACHE 1542/4885KDM4E 4112/4885MEN1 968/4885 |
| US-11795132-B2 | Application of metal hydride/palladium compound system in preparation of 1,3-dicarbonyl compound in cascade reaction of electron-deficient alkene compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HVCN1, HRH4 | ACHE 3399/4885KDM4E 924/4885MEN1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.